Literature DB >> 27687964

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

David Rice1, Kari Chansky2, Anna Nowak3, Harvey Pass4, Hedy Kindler5, Lynn Shemanski2, Isabelle Opitz6, Sergi Call7, Seiki Hasegawa8, Kemp Kernstine9, Cansel Atinkaya10, Federico Rea11, Philippe Nafteux12, Valerie W Rusch13.   

Abstract

INTRODUCTION: Nodal categories for malignant pleural mesothelioma are derived from the lung cancer staging system and have not been adequately validated. The International Association for the Study of Lung Cancer developed a multinational database to generate evidence-based recommendations to inform the eighth edition of the TNM classification of malignant pleural mesothelioma.
METHODS: Data from 29 centers were entered prospectively (n = 1566) or by transfer of retrospective data (n = 1953). Survival according to the seventh edition N categories was evaluated using Kaplan-Meier survival curves and Cox proportional hazards regression analysis. Survival was measured from the date of diagnosis.
RESULTS: There were 2432 analyzable cases: 1603 had clinical (c) staging, 1614 had pathologic (p) staging, and 785 had both. For clinically staged tumors there was no separation in Kaplan-Meier curves between cN0, cN1 or cN2 (cN1 versus cN0 hazard ratio [HR] = 1.06, p = 0.77 and cN2 versus cN1 HR = 1.04, p = 0.85). For pathologically staged tumors, patients with pN1 or pN2 tumors had worse survival than those with pN0 tumors (HR = 1.51, p < 0.0001) but no survival difference was noted between those with pN1 and pN2 tumors (HR = 0.99, p = 0.99). Patients with both pN1 and pN2 nodal involvement had poorer survival than those with pN2 tumors only (HR = 1.60, p = 0.007) or pN0 tumors (HR = 1.62, p < 0.0001).
CONCLUSIONS: A recommendation to collapse both clinical and pN1 and pN2 categories into a single N category comprising ipsilateral, intrathoracic nodal metastases (N1) will be made for the eighth edition staging system. Nodes previously categorized as N3 will be reclassified as N2.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer staging; Database; Mesothelioma; Nodal metastases

Mesh:

Year:  2016        PMID: 27687964     DOI: 10.1016/j.jtho.2016.09.121

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  29 in total

1.  Deciduoid type malignant pleural mesothelioma: a case report.

Authors:  Riki Okita; Yuji Nojima; Shinsuke Saisho; Katsuhiko Shimizu; Ryo Shirai; Naoki Kanomata; Mikio Oka; Masao Nakata
Journal:  AME Case Rep       Date:  2018-10-04

Review 2.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

3.  Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.

Authors:  Ori Wald; David J Sugarbaker
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 4.  Extended pleurectomy decortication: the current role.

Authors:  Rocco Bilancia; Marco Nardini; David A Waller
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 5.  The eighth TNM classification for malignant pleural mesothelioma.

Authors:  Lawek Berzenji; Paul E Van Schil; Laurens Carp
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 6.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

7.  Malignant pleural mesothelioma-the impact of globalization on rare diseases.

Authors:  M Alireza Hoda; Till Ploenes; Clemens Aigner
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

8.  Staging in the era of international databases: documented improvements with remaining challenges.

Authors:  Robert B Cameron
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Authors:  Zachary E Tano; Navin K Chintala; Xiaoyu Li; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2017-06

10.  Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis.

Authors:  Yonggang Yuan; Ge Ma; YaQi Zhang; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.